Homegrown preoperative lung cancer drug Leclaza lowers cancer stages in 55% of patients
A study by Korean researchers has confirmed that nine weeks of upfront treatment with the new homegrown anticancer drug Lexarza can lower the stage of inoperable lung cancer patients with EGFR gene mutations detected by lung lavage fluid biopsy, making …